AMGN Amgen Inc.

-5  -3%
Previous Close 182.47
Open 183.24
Price To Book 8.75
Market Cap 109312536646
Shares 615,949,381
Volume 8,266,572
Short Ratio
Av. Daily Volume 2,800,067

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Chronic Heart Failure
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Cardiovascular disease
sBLA approval announced January 5, 2017.
Multiple Myeloma
FDA approval announced October 1, 2018.
Multiple Myeloma
sNDA approved January 17, 2018.
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Phase 3 data released January 24, 2019 - primary endpoint met.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
CRL issued June 1, 2018.
ABP 980
Herceptin biosimilar
BLA filing announced December 17, 2018.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Secondary hyperparathyroidism (SHPT)
FDA Approval announced April 9, 2019.
EVENITY (Romosozumab)
Phase 3 interim analysis March 20, 2019 noted trial to continue as planned. Enrolment to be completed 1H 2019.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data at ASH December 2018 noted 7/42 CRs
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
sNDA filing announced December 19, 2018.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data due 2019.
Multiple Myeloma
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. The Top 10 Biotechnology Companies (JNJ, ROG.VX)
  2. Can Q1 Earnings Lift Healthcare ETFs Higher?
  3. 3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and Amgen
  4. Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
  5. Amgen Falls 3%
  6. Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
  7. Why Amgen Stock Could Break Out to New Highs
  8. Amgen sets $21,900 annual price for new Evenity bone drug
  9. EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
  10. The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global
  11. Goldman Sachs's 20 best stocks to invest in now
  12. Better Buy: Amgen vs. Gilead Sciences
  13. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  14. Top Analyst Reports for Bank of America, Amgen & NextEra Energy
  15. Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
  16. 8 Stocks May Jump on Takeovers as Market Nears Peak
  17. 8 Stocks to Own in 2Q as the Market Enters Rough Waters
  18. Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
  19. Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
  20. Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug